Cited by 155Cancer-related Molecular PathwaysDevelopmental Biology and Gene RegulationCell death mechanisms and regulation

Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development

Open access
Xiong, Shunbin, Van Pelt, Carolyn S., Elizondo-Fraire, Ana C., Liu, Geng, Lozano, Guillermina·2006·Proceedings of the National Academy of Sciences

Abstract

Loss of Mdm2 or Mdm4 leads to embryo lethal phenotypes that are p53-dependent. To determine whether Mdm2 and Mdm4 inhibit p53 function redundantly in a more restricted cell type, conditional alleles were crossed to a neuronal specific Cre transgene to delete Mdm2 and Mdm4 in the CNS. Mice lacking Mdm2 in the CNS developed hydranencephaly at embryonic day 12.5 due to apoptosis, whereas Mdm4 deletion showed a proencephaly phenotype at embryonic day 17.5 because of cell cycle arrest and apoptosis. The deletion of both genes, strikingly, contributed to an even earlier and more severe CNS phenotype. Additionally, Mdm2 and Mdm4 had a gene dosage effect, because loss of three of the four Mdm alleles also showed a more accelerated CNS phenotype than deletion of either gene alone. All phenotypes were rescued by deletion of p53. Thus, these in vivo data demonstrate the importance of Mdm4 independent of Mdm2 in inhibition of p53.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0508500103

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In smooth muscle cells, loss of Mdmx has no phenotype.

    “However, in other cases, such as smooth muscle cells, loss of Mdmx has no phenotype.”

    From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [40]

  • Mdm2 and Mdmx contribute to p53 regulation to different extents in different tissues in vivo.

    “Mdm2 and Mdmx seem to contribute to p53 regulation to different extents in different tissues in vivo (Table 1; [32–40]).”

    From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [40]

  • In some tissues and cell types, such as the central nervous system and proliferative intestinal cells, there is a requirement for both Mdm2 and Mdmx.

    “Clearly in some tissues and cell types [such as the central nervous system (CNS) and proliferative intestinal cells], there is a requirement for both Mdm2 and Mdmx.”

    From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [40]

  • Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo and that they exert non-overlapping inhibitory activities towards p53.

    “Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108 and that they exert non-overlapping inhibitory activities towards p53 (Refs 24,109).”

    From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [109]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [29]O'Rourke, N. A., Sullivan, D. P., Kaznowski, C. E., Jacobs, A. A. & McConnell, S. K. (1995) Development (Cambridge, U.K.) 121, 2165-2176.
  2. [37]Linares, L. K., Hengstermann, A., Ciechanover, A., Muller, S. & Scheffner, M. (2003) Proc. Natl. Acad. Sci. USA 100, 12009-12014.
  3. [41]Carroll, P. M., Tsirka, S. E., Richards, W. G., Frohman, M. A. & Strickland, S. (1994) Development (Cambridge, U.K.) 120, 3173-3183.

Cited by

Sorted by citations

Authors
Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., & Lozano, G.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Veterinary Medicine and Surgery, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030
  • Departments of *Molecular Genetics and
Venue
Proceedings of the National Academy of Sciences
Published
2006-02-21
Volume
103
Issue
9
Pages
3226-3231
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1967632402
Cited by
155
References
43
Citations by year
2025: 3 · 2024: 3 · 2023: 5 · 2022: 3 · 2020: 6 · 2019: 2 · 2018: 4 · 2017: 8 · 2016: 9 · 2015: 5 · 2014: 7 · 2013: 7 · 2012: 15
FWCI
8.87
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (CA-16672, CA47296, R01CA047296, P30CA016672)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
MDM2, MDM4, p53, p53 inhibition, central nervous system development, hydranencephaly, apoptosis, cell cycle arrest, gene dosage effect, conditional gene deletion, embryonic lethality
MeSH terms
Animals, Animals, Newborn, Central Nervous System, Female, Genes, Lethal, Mice, Transgenic, Phenotype, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Apoptosis, Gene Expression Regulation, Developmental, Ubiquitin-Protein Ligases, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review